Sensyne Health PLC - Sensyne Health achieves 5 million patient target
Sensyne Health achieves five million patient target
set at IPO
~ NHS equity ownership in Sensyne now 11.7% ~
~ Sensyne model shows benefit to NHS and
The new SRA now brings the combined total of anonymised patient data available for analysis by Sensyne to 5.6 million patients. The data enables the ethical application of clinical artificial intelligence research on anonymised patient data to improve patient care and accelerate research into new medicines.
In line with the strategy laid out at the time of its IPO, with access now to anonymised data on more than five million patients, Sensyne is able to cover a broader range of research across different clinical areas, deliver powerful data insights to speed up the development of novel approaches to new medicines, and develop AI-powered clinical decision support tools to improve patient care.
The unique nature of Sensyne's business model, where NHS Trusts receive an equity stake in the Company, a royalty on revenues that are generated from research undertaken under the SRAs and an investment of up to
Research conducted by Sensyne using SRA data includes:
· Stroke prediction - identifying additional risk factors to help clinicians better predict stroke and improve care.
· Heart failure treatment - identifying specific subgroups of patients suffering from heart failure to help personalise treatments that are effective for particular patient groups.
· COVID-19 lung impact - developing algorithms using computer vision for the analysis of images to detect COVID-19 related lung disease.
· COVID-19 risk - developed algorithms to predict the risk of intensive care unit admission, invasive mechanical ventilation and death in patients with COVID-19 infection.
"Reaching this five million patient milestone with our NHS Trust partners is a great achievement and means that together we have created a world-class medical research capability here in the
"We are experiencing enthusiasm from other NHS Trusts across the
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
| || |
Consilium Strategic Communications
+44 (0) 7780 600290
| || |
| || |
| || |
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
 As at the mid-price close on 13/11/20. Excludes
Quick facts: Sensyne Health PLC
Market Cap: £250.56 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE